NCT02507583 2025-05-07
Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
Thomas Jefferson University
Phase 1 Completed
Thomas Jefferson University
Bristol-Myers Squibb
Banaras Hindu University
Institut Cancerologie de l'Ouest
Peking University People's Hospital
University Health Network, Toronto
INSYS Therapeutics Inc
St. Jude Children's Research Hospital